These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 22522223)

  • 1. Is early detection of cancer with circulating biomarkers feasible?
    Konforte D; Diamandis EP
    Clin Chem; 2013 Jan; 59(1):35-7. PubMed ID: 22522223
    [No Abstract]   [Full Text] [Related]  

  • 2. Ovarian cancer early detection claims are biased.
    McIntosh M; Anderson G; Drescher C; Hanash S; Urban N; Brown P; Gambhir SS; Coukos G; Laird PW; Nelson B; Palmer C
    Clin Cancer Res; 2008 Nov; 14(22):7574; author reply 7577-9. PubMed ID: 18948385
    [No Abstract]   [Full Text] [Related]  

  • 3. [Clinical validation of multiple biomarkers suspension array technology for ovarian cancer].
    Zhao BB; Yang ZJ; Wang Q; Pan ZM; Zhang W; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2017 Jan; 52(1):11-19. PubMed ID: 28190310
    [No Abstract]   [Full Text] [Related]  

  • 4. Early detection of epithelial ovarian cancer using a proteomics-based protein-profiling approach combined with a novel selection strategy.
    Kothandaraman N; Bajic VB; Loganath A; Koh S; Ng J; Choolani M; Razvi K
    Ann Acad Med Singap; 2004 Sep; 33(5 Suppl):S59-60. PubMed ID: 15651211
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical practice. Screening for ovarian cancer.
    Clarke-Pearson DL
    N Engl J Med; 2009 Jul; 361(2):170-7. PubMed ID: 19587342
    [No Abstract]   [Full Text] [Related]  

  • 6. Emerging diagnostic, prognostic and therapeutic biomarkers for ovarian cancer.
    El Bairi K; Kandhro AH; Gouri A; Mahfoud W; Louanjli N; Saadani B; Afqir S; Amrani M
    Cell Oncol (Dordr); 2017 Apr; 40(2):105-118. PubMed ID: 27981507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evaluation of selected serum protein markers as early detectors of ovarian cancer].
    Mrochem J; Sodowski K; Deja R; Walaszek-Gruszka A; Wojcieszek A; Kołosza Z; Chmura A; Czernik E; Masłyk B; Bartnik W; Cnota W
    Ginekol Pol; 2008 Apr; 79(4):271-5. PubMed ID: 18592865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differentiating stage I epithelial ovarian cancer from benign disease in women with adnexal tumors using biomarkers or the ROMA algorithm.
    Kaijser J; Van Gorp T; Sayasneh A; Vergote I; Bourne T; Van Calster B; Timmerman D
    Gynecol Oncol; 2013 Aug; 130(2):398-9. PubMed ID: 23656998
    [No Abstract]   [Full Text] [Related]  

  • 9. Differentiating stage I epithelial ovarian cancer from benign disease in women with adnexal tumours using biomarkers or the ROMA algorithm.
    Kondalsamy-Chennakesavan S; Obermair A
    Gynecol Oncol; 2013 Aug; 130(2):400. PubMed ID: 23660370
    [No Abstract]   [Full Text] [Related]  

  • 10. Blood and urine markers for ovarian cancer: a comprehensive review.
    Terry KL; Sluss PM; Skates SJ; Mok SC; Ye B; Vitonis AF; Cramer DW
    Dis Markers; 2004; 20(2):53-70. PubMed ID: 15322314
    [No Abstract]   [Full Text] [Related]  

  • 11. Doctor, should I get this new ovarian cancer test-OVA1?
    Muller CY
    Obstet Gynecol; 2010 Aug; 116(2 Pt 1):246-247. PubMed ID: 20664381
    [No Abstract]   [Full Text] [Related]  

  • 12. Status of tumor markers in ovarian cancer screening.
    Bast RC
    J Clin Oncol; 2003 May; 21(10 Suppl):200s-205s. PubMed ID: 12743135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Pilot Study of Circulating MicroRNA-125b as a Diagnostic and Prognostic Biomarker for Epithelial Ovarian Cancer.
    Zhu T; Gao W; Chen X; Zhang Y; Wu M; Zhang P; Wang S
    Int J Gynecol Cancer; 2017 Jan; 27(1):3-10. PubMed ID: 27636713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in the early detection of ovarian cancer: How to hear the whispers early.
    Cesario S
    Nurs Womens Health; 2010 Jun; 14(3):222-34. PubMed ID: 20579298
    [No Abstract]   [Full Text] [Related]  

  • 15. The serine protease prostasin (PRSS8) is a potential biomarker for early detection of ovarian cancer.
    Tamir A; Gangadharan A; Balwani S; Tanaka T; Patel U; Hassan A; Benke S; Agas A; D'Agostino J; Shin D; Yoon S; Goy A; Pecora A; Suh KS
    J Ovarian Res; 2016 Mar; 9():20. PubMed ID: 27036110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Interleukin 6 (IL-6)--a biological marker in patients with ovarian cancer?].
    Schröder W; Ruppert C; Bender HG
    Gynakol Geburtshilfliche Rundsch; 1993; 33 Suppl 1():200-1. PubMed ID: 8118269
    [No Abstract]   [Full Text] [Related]  

  • 17. Proteomic patterns in serum and identification of ovarian cancer.
    Diamandis EP
    Lancet; 2002 Jul; 360(9327):170; author reply 170-1. PubMed ID: 12126845
    [No Abstract]   [Full Text] [Related]  

  • 18. Summaries for patients. Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement.
    Ann Intern Med; 2012 Dec; 157(12):I-56. PubMed ID: 23362519
    [No Abstract]   [Full Text] [Related]  

  • 19. Circulating tumor cells as trigger to hematogenous spreads and potential biomarkers to predict the prognosis in ovarian cancer.
    Gasparri ML; Savone D; Besharat RA; Farooqi AA; Bellati F; Ruscito I; Panici PB; Papadia A
    Tumour Biol; 2016 Jan; 37(1):71-5. PubMed ID: 26500096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Changed RNase isoenzyme pattern in ovarian cancers].
    Schleich H; Ebert H; Wiest W; Hofmann I; Inthraphuvasak J; Melchert F
    Arch Gynecol Obstet; 1989; 245(1-4):646-8. PubMed ID: 2802750
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.